Surreal illustration of botox needles gently massaging a serene blue bladder.

Botox for MS: How It Can Ease Urinary Symptoms

Jordan Keane monogram
Jordan Keane in Health & Wellness October 2026 • 3 min read.

"Discover how Botulinum Toxin A (Botox) is revolutionizing the management of urinary issues in multiple sclerosis patients, offering improved quality of life and fewer side effects."


Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, often leading to a range of physical and neurological challenges. Among these, bladder dysfunction is a common and distressing symptom. Affecting a significant percentage of individuals with MS, bladder issues can greatly impact daily life, affecting everything from sleep patterns to social activities.

Traditionally, managing MS-related bladder problems has involved medications with varying degrees of success and side effects. However, a promising alternative has emerged: Botulinum Toxin A, more commonly known as Botox. While Botox is widely recognized for its cosmetic applications, its therapeutic potential extends to treating various medical conditions, including overactive bladder and urinary incontinence associated with MS.

This article explores the use of Botox as a treatment for urinary symptoms in MS patients, offering insights into how it works, its effectiveness, and what patients can expect from the procedure. We aim to provide clear, accessible information to empower individuals with MS to make informed decisions about their care.

AI Search Multiple angles on this topic

Monitoring During Treatment

NICE recommends monitoring residual urine volume during botulinum toxin type A treatment for people who are not using a catheterisation regimen. The recommendation highlights a practical aspect of care during treatment, rather than providing a prevalence or impact statistic for urinary symptoms in MS.

Botulinum Toxin in Spasticity Care

A 2026 single-center retrospective study describes botulinum toxin type A (BoNT-A) as a safe and effective treatment for spasticity in people with MS and post-stroke spasticity. It compared injection patterns and dosages in 33 people with MS and 55 with post-stroke spasticity. A 2025 review focused on ways to enhance BoNT’s neuromuscular effects in MS-related spasticity, including adjunctive therapies aimed at reducing dosage; the supplied summaries do not specify which approaches proved effective.

Understanding Urinary Symptoms in MS

Surreal illustration of botox needles gently massaging a serene blue bladder.

Urinary symptoms in MS are often due to disruptions in the nerve pathways that control the bladder and urinary tract. MS-related lesions in the brain or spinal cord can interfere with the signals between the brain and the bladder, leading to a variety of issues.

The most common urinary symptoms experienced by individuals with MS include:

  • Frequency: An increased need to urinate throughout the day.
  • Urgency: A sudden, compelling urge to urinate that is difficult to delay.
  • Incontinence: The involuntary leakage of urine.
  • Nocturia: The need to wake up during the night to urinate.
  • Urinary Retention: Difficulty emptying the bladder completely.
AI Search Multiple angles on this topic

Recent Spasticity Research

A June 9, 2026 single-center retrospective study compared BoNT-A injection patterns and dosages in people with MS and people with post-stroke spasticity; its abstract describes the treatment as safe and effective for spasticity in both groups. A 2025 review examined adjunctive therapies intended to enhance BoNT effects or reduce dosage in MS-related spasticity. Another supplied source describes a study objective of testing segmental muscle vibration and BoNT-A, alone or combined, for reducing spasticity in people with MS. The snippets do not report results for the latter two lines of research.

Evidence Gaps and Caution

A systematic review and meta-analysis of intradetrusor onabotulinumtoxin for lower urinary tract symptoms in people with MS calls for larger multicenter studies to assess short- and long-term effects and appropriate dosage. A separate systematic review of neurogenic bladder prevalence says its exploratory estimates for storage, voiding, and mixed symptoms should be interpreted cautiously because few studies contributed. These sources point to limits in the evidence base, rather than establishing that treatment fails. The supplied Japanese study snippet suggests possible benefit for Japanese patients with MS, but frames this as a possibility based on favorable results in patients with spinal cord injury, not as a demonstrated MS result in that study.

Placebo-Controlled Trial Results

In a randomized, double-blind, placebo-controlled trial of urinary incontinence due to neurogenic detrusor overactivity, onabotulinumtoxinA doses of 200 U and 300 U significantly reduced weekly incontinence episodes at week 6 compared with placebo. The reported changes were −21.8 episodes per week with 200 U, −19.4 with 300 U, and −13.2 with placebo (p<0.01). Benefit was observed by the first post-treatment study visit at week 2. The supplied trial summary does not provide a direct comparison establishing that one active dose was superior to the other.

These symptoms can arise from two primary types of bladder dysfunction: detrusor overactivity (where the bladder muscle contracts involuntarily) and detrusor underactivity (where the bladder muscle is weak or inactive). In some cases, a combination of both issues may be present.

The Future of MS Symptom Management

As research continues and new treatments emerge, individuals with MS can look forward to a future with more effective and personalized approaches to managing their symptoms. Staying informed, working closely with healthcare providers, and exploring all available options are key to living well with MS.

AI Search Multiple angles on this topic

Questions for Future Research

A 2025 review set out to document approaches that might enhance botulinum toxin’s neuromuscular effects in MS-related spasticity, including adjunctive therapies aimed at reducing dosage. This points to an area of investigation, but the supplied summary does not identify proven strategies or report outcomes. The source material also describes Botox as an injectable treatment approved to ease spasticity in MS, but does not provide evidence here about future approval changes or new bladder indications.

Patient Experience and Real-World Evidence

A July 2025 report describes the study “Spasticity Management with Botulinum Toxin in Post-stroke and Multiple Sclerosis Patients: A Retrospective, ‘Real-world’, Multicenter Study,” published in NeuroRehabilitation. The supplied report title says most MS patients were satisfied with botulinum toxin for spasticity. However, the accompanying abstract summary notes a paucity of real-world data for MS and other conditions compared with the stronger evidence for post-stroke spasticity. A separate proof-of-concept study recruited nine people with MS to explore changes in migraine headaches and spasticity-plus syndrome symptoms after BoNT treatment; the snippet does not provide its results.

How dose comparisons and follow-up shape the evidence

The phase III results show fewer weekly incontinence episodes with either active dose than with placebo, while the reported figures alone do not establish which active dose is better.[1]

The catheterization results add a trade-off to the symptom findings: urinary retention led some participants who had not catheterized before treatment to begin doing so.[1]

A meta-analysis reports that its patient set was too limited for definite conclusions about efficacy and safety, despite adding randomized trials to an earlier review.[2]

Repeated injections were associated with an acceptable response for more than three months in the studied NDO patients, but the available data were insufficient to establish long-term efficacy and safety.[2]

What remains uncertain about bladder Botox

  • Would a direct comparison clarify how the lower-dose MS results relate to the phase III dose findings, given that the reported comparison uses a subset from separate trials?[3]
  • How durable are the benefits and safety findings beyond the follow-up described, since long-term evidence remains insufficient?[2]

Terms used in the bladder findings

Temporary chemodenervation
Temporary reduction of nerve-driven muscle activity through blocking presynaptic acetylcholine release.[4]

Sources

  1. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. (pubmed.ncbi.nlm.nih.gov)
  2. Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (pmc.ncbi.nlm.nih.gov)
  3. Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS (pmc.ncbi.nlm.nih.gov)
  4. Onabotulinumtoxin intra-detrusor injection for lower urinary tract symptoms (LUTS) in patients with multiple sclerosis (MS): A systematic review and meta-analysis (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is Botulinum Toxin A and how does it help with urinary symptoms in MS?

Botulinum Toxin A, commonly known as Botox, is a treatment used to manage urinary symptoms associated with multiple sclerosis (MS). MS can disrupt nerve pathways controlling the bladder, leading to issues like frequency, urgency, and incontinence. Botox helps by targeting bladder dysfunction, specifically overactive bladder, providing an alternative to traditional medications with potentially fewer side effects. It's significant because it can improve the quality of life for those with MS by alleviating distressing urinary symptoms.

2

Why do people with multiple sclerosis often experience urinary problems?

Urinary symptoms such as frequency, urgency, incontinence, nocturia and urinary retention are common in multiple sclerosis because MS affects the central nervous system. Lesions in the brain or spinal cord disrupt signals between the brain and bladder. This interference can cause the bladder to contract involuntarily (detrusor overactivity) or become weak and inactive (detrusor underactivity), leading to these various urinary problems. Managing these symptoms is crucial for maintaining a good quality of life.

3

How does Botulinum Toxin A actually work to alleviate urinary symptoms?

Botox addresses urinary symptoms in MS by targeting the bladder muscles. When injected into the bladder, Botulinum Toxin A helps to relax the muscles, reducing involuntary contractions. This is particularly helpful in cases of detrusor overactivity, where the bladder muscle contracts too frequently. By controlling these contractions, Botox can decrease the urgency and frequency of urination, as well as reduce incidents of incontinence. The result is improved bladder control and fewer disruptive urinary symptoms.

4

In what ways can bladder problems from MS affect daily life?

MS-related bladder issues can significantly impact daily life. The constant need to urinate (frequency), the sudden urge to urinate (urgency), and involuntary leakage (incontinence) can disrupt sleep, limit social activities, and affect overall well-being. Nocturia, the need to wake up at night to urinate, further disturbs sleep patterns. By managing these symptoms with treatments like Botox, individuals with MS can regain a sense of control over their bodies and improve their quality of life.

5

What are detrusor overactivity and detrusor underactivity, and how are they related to bladder problems in MS?

Detrusor overactivity refers to a condition where the bladder muscle contracts involuntarily, leading to a frequent and urgent need to urinate. Detrusor underactivity, on the other hand, involves a bladder muscle that is weak or inactive, making it difficult to empty the bladder completely. Both conditions can result from nerve damage caused by MS. Understanding which type of bladder dysfunction is present is crucial for determining the most appropriate treatment strategy. Botox is primarily used for detrusor overactivity, helping to relax the bladder muscle and reduce involuntary contractions.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.